Cargando…

Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients

In spite of intensive treatment Type 1 diabetes leads to serious complications. Preservation of residual beta cell function makes the disease milder, facilitates treatment, prevents complications and increase survival. So far immune interventions have had limited effect, and some serious adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casas, Rosaura, Dietrich, Fabrícia, Barcenilla, Hugo, Tavira, Beatriz, Wahlberg, Jeanette, Achenbach, Peter, Ludvigsson, Johnny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583358/ https://www.ncbi.nlm.nih.gov/pubmed/33162978 http://dx.doi.org/10.3389/fimmu.2020.564921

Ejemplares similares

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
por: Tavira, Beatriz, et al.
Publicado: (2018)

Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype
por: Puente-Marin, Sara, et al.
Publicado: (2023)

Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
por: Casas, Rosaura, et al.
Publicado: (2022)

Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2022)

Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
por: Ludvigsson, Johnny, et al.
Publicado: (2021)

Mass Cytometry Identifies Distinct Subsets of Regulatory T Cells and Natural Killer Cells Associated With High Risk for Type 1 Diabetes
por: Barcenilla, Hugo, et al.
Publicado: (2019)

Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes
por: Åkerman, Linda, et al.
Publicado: (2018)

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017)

Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial
por: Ludvigsson, Johnny, et al.
Publicado: (2020)

Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes
por: Nowak, Christoph, et al.
Publicado: (2022)

Three Distinct Glutamate Decarboxylase Genes in Vertebrates
por: Grone, Brian P., et al.
Publicado: (2016)

Molecular Analysis of Glutamate Decarboxylases in Enterococcus avium
por: Gu, Xinyi, et al.
Publicado: (2021)

Increase of Neutrophil Extracellular Traps, Mitochondrial DNA and Nuclear DNA in Newly Diagnosed Type 1 Diabetes Children but Not in High-Risk Children
por: Skoglund, Camilla, et al.
Publicado: (2021)

Neurological Disorders Associated with Glutamic Acid Decarboxylase Antibodies
por: Herard, Kimberly, et al.
Publicado: (2019)

Parallel Strategy Increases the Thermostability and Activity of Glutamate Decarboxylase
por: Zhang, Qing-Fei, et al.
Publicado: (2020)

Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
por: Axelsson, Stina, et al.
Publicado: (2013)

Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes
Publicado: (1995)

Calmodulin-dependent and calmodulin-independent glutamate decarboxylases in apple fruit
por: Trobacher, Christopher P, et al.
Publicado: (2013)

Anti-glutamic acid decarboxylase antibody positive neurological syndromes
por: Tohid, Hassaan
Publicado: (2016)

Neurological Manifestations of Glutamic Acid Decarboxylase Autoimmunity in Indian Patients
por: Thevarkalam, Meena, et al.
Publicado: (2023)

Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets
por: Magnusson, Louise, et al.
Publicado: (2020)

Upbeat Nystagmus in Late Onset Cerebellar Ataxia: Think of Anti-Glutamate Decarboxylase 65 Antibody-Associated Cerebellar Ataxia
por: Mahale, Rohan R., et al.
Publicado: (2021)

High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus
por: Paulsson, Johan F., et al.
Publicado: (2014)

Lessons From the Mixed-Meal Tolerance Test: Use of 90-minute and fasting C-peptide in pediatric diabetes
por: Besser, Rachel E.J., et al.
Publicado: (2013)

Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol
por: Ludvigsson, Johnny, et al.
Publicado: (2022)

Normal Incidence of Diabetes in NOD Mice Tolerant to Glutamic Acid Decarboxylase
por: Jaeckel, Elmar, et al.
Publicado: (2003)

Limbic encephalitis with antibodies to glutamic acid decarboxylase presenting with brainstem symptoms
por: Incecik, Faruk, et al.
Publicado: (2015)

Identification and molecular cloning of glutamate decarboxylase gene from Lactobacillus casei
por: Tavakoli, Yasaman, et al.
Publicado: (2015)

Increased glutamic acid decarboxylase expression in the hypothalamic suprachiasmatic nucleus in depression
por: Wu, Xueyan, et al.
Publicado: (2017)

Hippocampus and Insula Are Targets in Epileptic Patients With Glutamic Acid Decarboxylase Antibodies
por: Falip, Mercè, et al.
Publicado: (2019)

Pathogenic Roles of Glutamic Acid Decarboxylase 65 Autoantibodies in Cerebellar Ataxias
por: Mitoma, Hiroshi, et al.
Publicado: (2017)

Global knockdown of glutamate decarboxylase 67 elicits emotional abnormality in mice
por: Miyata, Shigeo, et al.
Publicado: (2021)

Increased diagnosis of autoimmune childhood‐onset Japanese type 1 diabetes using a new glutamic acid decarboxylase antibody enzyme‐linked immunosorbent assay kit, compared with a previously used glutamic acid decarboxylase antibody radioimmunoassay kit
por: Sugihara, Shigetaka, et al.
Publicado: (2019)

Contribution of glutamate decarboxylase in Lactobacillus reuteri to acid resistance and persistence in sourdough fermentation
por: Su, Marcia S, et al.
Publicado: (2011)

Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia
por: Manto, Mario U, et al.
Publicado: (2011)

Glutamate decarboxylase 67 contributes to compensatory insulin secretion in aged pancreatic islets
por: Cho, Jung Hoon, et al.
Publicado: (2019)

Glutamic acid decarboxylase antibodies in neurocritical patients: a culprit or a bystander?
por: Wang, Dongmei, et al.
Publicado: (2020)

Epilepsy in patients with insulin-dependent diabetes and relation to glutamic acid decarboxylase 65
por: Mahmoud, Adel A., et al.
Publicado: (2020)

The clinical relevance of anti-glutamic acid decarboxylase antibodies in children with encephalitis/encephalopathy
por: Hou, Ju-Yin, et al.
Publicado: (2023)

Glutamate decarboxylase 1 gene polymorphisms are associated with respiratory symptoms in panic disorder
por: Zou, Zhi-Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kbc9ks1ghrah3p9opbfrkqhrga